Navigation Links
Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer
Date:5/31/2009

glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward-looking" statements. These include statements concerning the potential for TELCYTA to treat ovarian cancer, the effectiveness of TELCYTA in combination with PLD and in patients under certain platinum refractory and platinum resistant conditions, and the effectiveness of TELCYTA upon stomatitis and PPE associated with PLD. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including the risks associated with clinical trials and the interpretation of resulting data. Detailed information regarding these and other factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended March 31, 2009. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Telik Announces Preclinical Presentations at AACR Annual Meeting
2. Telik Announces Fourth Quarter and 2008 Year End Financial Results and 2009 Financial Guidance
3. Telik Announces Year-End Financial Release, Conference Call and Webcast
4. Telik Announces Patents on Compounds Related to TELINTRA
5. Telik Announces Preclinical Presentations at AACR Annual Meeting
6. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
7. Lumenis(R) Presents the SlimLine(TM) GI Laser Fiber: The Latest Advancement in Laser Lithotripsy for Gastroenterology
8. Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook
9. AGA Institute presents cutting-edge research during DDW
10. The Pediatric IBD Center at Cedars-Sinai Medical Center Presents Rock-n-Reel 2009 Honoring Alexandra Milchan-Lambert & Scott Lambert
11. Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 DON’T PAUSE ... help alleviate uncomfortable bloating, hot flashes, mood swings, burning ... identified by Dr. Shoreh Ershadi. The AntiAging Institute of California ... Menopause that allows women to try this revolutionary product. For ... PAUSE can get a third bottle at no charge. ...
(Date:7/25/2014)... and desires in initial romantic encounters determine the fate ... those initial "sparks" necessary to fuel sexual desire and ... a desirable trait for both men and women on ... the other person? Do men perceive responsive women as ... women,s perceptions of men? A study published in ...
(Date:7/25/2014)... Researchers at the University of Bordeaux in Bordeaux, France have ... man-made material used in high-heat insulation may increase the risk ... has just posted an article on the new study. ... French scientists studied the work histories of 988 men ... group of workers had been exposed to asbestos only while ...
(Date:7/25/2014)... York, NY (PRWEB) July 25, 2014 ... for the Guinness International Champions Cup Match between Manchester ... Bronx, New York, one of the most iconic locations is ... original Yankee Stadium, but it is quickly becoming a location ... The facility is home to the New York Yankees from ...
(Date:7/25/2014)... 25, 2014 CMS recently has imposed ... for providing inadequate access to prescription drugs. Agency audits ... health and safety of beneficiaries in areas such as ... and CMS is taking quick and firm actions to ... Services webinar, “Avoiding Costly Part D Sanctions: Rx ...
Breaking Medicine News(10 mins):Health News:AntiAging Institute of California Now Offers DON'T PAUSE for Menopause with a Special Promotion 2Health News:Why do men prefer nice women? 2Health News:Why do men prefer nice women? 3Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 2Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 3Health News:Manchester City vs. Liverpool FC Tickets Yankee Stadium: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match in NYC on July 30th 2Health News:Manchester City vs. Liverpool FC Tickets Yankee Stadium: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match in NYC on July 30th 3Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2
... , NASHVILLE, Tenn. and GLEN ROCK, N.J., ... 76 percent of surveyed pharmacy directors say that by ... only one preferred biologic for all immune conditions, such ... According to the new Formulary Forum report entitled ...
... , , , ... GHDX ) today announced that Kim Popovits, Genomic Health,s Chief ... Growth Conference in Boston, on Thursday, August 13 at 1:30 p.m. ... subsequently archived webcast of the presentation, visit the Investor Relations section ...
... , , HOUSTON, Aug. 6 ... a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated ... trial is being conducted under a Bellicum Investigational New Drug application ... results of the study in 2010. , , ...
... , , KIBBUTZ SHAMIR, ... SHMR ) (" Shamir ") expects to issue its second quarter ... a conference call to discuss the results at 11:00 A.M. EDT that ... broadcast live as a listen-only webcast. To listen live, please go to ...
... , , NEW YORK, ... synthetic peptide technology shown to significantly help improve the appearance of ... now available through select physicians to help their patients achieve picture ... can be found in leading physician offices for $120 per 1 ...
... , SALT LAKE CITY, Aug. 6 ... silicon nitride ceramic technologies, announced today that Ben Shappley has joined ... Shappley will also serve on the company,s Board of Directors. , ... of orthopaedic and neurosurgical implant experience in both management and senior ...
Cached Medicine News:Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 2Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 3Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 2Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Second Quarter of 2009 Earnings Results 2Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 2Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 3Health News:Ben Shappley Joins Amedica's Leadership Team 2
(Date:7/24/2014)... 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a ... announced its financial results for the second quarter ended June ... , Total revenues of $6.5 million in the second quarter ... in 2013 , Total revenues of $13.3 million for ... 78% over the same period in 2013 , Total ...
(Date:7/24/2014)... July 24, 2014 LSI Medience Corporation ... Agreement with Kineticos, a Raleigh-Durham, NC ... will support LSI Medience in identifying opportunities for ... demonstrate utility in clinical trials. The ... in diagnosis of sepsis, prognosis of septic patients, ...
(Date:7/24/2014)... , July 24, 2014  The American ... is supporting its mission to help address audit ... and exclusive agreement to be the information technology ... As the leading provider of billing and business ... unmatched HME industry expertise to support this important ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2
... ONXX ) today announced that it will present at the Canaccord ... a.m. Eastern Time ( 5:00 a.m. Pacific Time ). , ... Interested parties may access a live webcast of the presentation on our website ... It is recommended that ...
... Aug. 3 On June 9, 2010 , Invivo was recognized ... and DynaTRIM (Trans-Rectal Interventional MRI) clinical solutions. The MDEA awards ceremony took place in ... gold and silver winners were honored. , , ... (Photo:   http://photos.prnewswire.com/prnh/20100803/SF44927 ) , , , ...
Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Canaccord Genuity 30th Annual Growth Conference 2Invivo Wins Medical Design Excellence Award for Prostate Solutions 2Invivo Wins Medical Design Excellence Award for Prostate Solutions 3
... a differential medium designed for the ... Selective agents are incorporated for the ... of S. epidermidis and yeast. S. ... in mauve colonies, thus permitting differentiation ...
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
... a 180 watt Xenon short arc lamp. Designed to ... the lamp to the light guide, this light source ... higher watt bulbs. A new IR filtering system and ... amount of heat generated from the light source and ...
... standardize your video equipment has led Linvatec ... couplers to accommodate all of your multi-specialty ... "V mount couplers in both traditional eyecup ... also offer a 20-42mm Zoom "C mount ...
Medicine Products: